Company Profile
Aquestive Therapeutics Stock Price, News & Analysis
- Ticker:
- AQST
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.92 USD (+4.39%)
Close
Last updated: August 6, 2026
493M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AQST closed up 4.39% at $3.92. No new same-company headline was identified in the current news window.
Company overview
Oral Film Drug Delivery Company
Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions.
Anaphylm
Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without water or swallowing.
PharmFilm Platform
Aquestive’s film technology controls drug loading, disintegration, and absorption in a compact dosage form and can be adapted across central nervous system and allergy products.
Non-Injectable Epinephrine Strategy
The product is intended to offer portable and intuitive epinephrine administration without an autoinjector, while producing clinically relevant systemic exposure.
Global Regulatory Opportunity
Aquestive plans to use the existing clinical package for regulatory applications in Canada, the European Union, and the United Kingdom alongside the U.S. program.
Future catalysts
Aquestive plans to resubmit the Anaphylm NDA to the FDA in the third quarter of 2026 after completing required human-factors and pharmacokinetic work.
Recent news
- 01
- 02
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Source: Aquestive Therapeutics
- 03
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Aquestive Therapeutics
- 04
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Source: Aquestive Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aquestive Therapeutics (AQST)?
Aquestive Therapeutics (AQST) most recently closed at 3.92 USD, a +4.39% move versus the previous session.
What is the market cap of Aquestive Therapeutics (AQST)?
Aquestive Therapeutics currently has a market capitalization of 493M USD on BioPharmSignal.
What does Aquestive Therapeutics do?
Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without water or...
On which exchange is AQST stock listed?
Aquestive Therapeutics (AQST) is associated with NASDAQ, United States, Biopharma.
What is Oral?
Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions.
Which conditions is Aquestive Therapeutics targeting with Oral?
Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without water or...
How does Aquestive Therapeutics describe recent progress with Oral?
Aquestive plans to resubmit the Anaphylm NDA to the FDA in the third quarter of 2026 after completing required human-factors and pharmacokinetic work.
What is Film?
Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions.